Company intelligence / Profile preview

Medical Enterprises Europe

Amsterdam, North Holland, Netherlandssynergo-medical.com ↗

Ownership: Private
Development stage: Commercial

Overview

The Synergo system by Medical Enterprises Europe provides a minimally invasive treatment for non-muscle-invasive bladder cancer using radiofrequency-induced thermochemotherapy. Clinical results show high rates of bladder preservation and improved outcomes in intermediate/high-risk and BCG-unresponsive patients. The technology has been evaluated by NICE with positive health economic impact.

Therapeutic areas: Oncology
Modalities: DeviceRadiofrequency-based therapyHyperthermia therapyChemotherapy delivery system (device-enabled)
Industry: Therapeutic Medical Devices

Beyond the preview

Go deeper on Medical Enterprises Europe.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Medical Enterprises Europe.

Explore the full profile